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Abstract
AIM: To investigate whether a fuzzy logic model could 
predict colorectal cancer (CRC) risk engendered by 
smoking in hereditary non-polyposis colorectal cancer 
(HNPCC) patients. 
METHODS: Three hundred and forty HNPCC mismatch 
repair (MMR) mutation carriers from the Creighton 
University Hereditary Cancer Institute Registry were 
selected for modeling. Age-dependent curves were 
generated to elucidate the joint effects between gene 
mutation (hMLH1 or hMSH2), gender, and smoking 
status on the probability of developing CRC. 
 
RESULTS: Smoking significantly increased CRC risk 
in male hMSH2 mutation carriers (P  < 0.05). hMLH1 
mutations augmented CRC risk relative to hMSH2 
mutation carriers for males (P  < 0.05). Males had a 
significantly higher risk of CRC than females for hMLH1 
non smokers (P  < 0.05), hMLH1 smokers (P  < 0.1) and 
hMSH2 smokers (P  < 0.1). Smoking promoted CRC in a 
dose-dependent manner in hMSH2 in males (P  < 0.05). 
Females with hMSH2 mutations and both sexes with the 
hMLH1 groups only demonstrated a smoking effect after 
an extensive smoking history (P  < 0.05). 
CONCLUSION: CRC promotion by smoking in HNPCC 
patients is dependent on gene mutation, gender and 
age. These data demonstrate that fuzzy modeling 
may enable formulation of clinical risk scores, thereby 
allowing individualization of CRC prevention strategies.
© 2006 The WJG Press. All rights reserved.
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INTRODUCTION
Accurate risk-stratification is essential for combating the 
50 000 yearly deaths from colorectal cancer (CRC) in the 
United States[1]. The best-established risk factor is a familial 
predisposition to CRC, which is implicated in one-quarter 
of  all CRC cases[2]. While determining a family history can 
be readily accomplished, risk quantification which is critical 
for tailoring screening strategies, remains remarkably 
imprecise. For instance, even in documented carriers of  
CRC predisposing genes, clinical expression can be quite 
varied due to modulation by numerous confounding 
endogenous and exogenous variables[3,4].
    Hereditary non-polyposis colorectal cancer (HNPCC) 
represents a case in point. This autosomal dominant 
condition is the most common cancer predisposing 
syndrome engendering a > 70% lifetime risk of  developing 
CRC[5]. Furthermore, we have recently demonstrated that 
cigarette smoking of  a male carrying hMLH1 mutations 
(versus hMSH2) increases the hazard of  CRC by 1.4-, 1.6- 
and 2.0-fold respectively[6]. However, optimal management 
strategies (colonoscopic surveillance versus prophylactic 
colectomy) are unclear secondary to characteristic 
phenotypic heterogeneity, i.e. marked variations in age of  
onset of  cancers[7]. Thus, HNPCC represents an excellent 
paradigm to study the gene-environment joint effect 
hypothesis.
    Incorporating these important findings into clinical 
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practice is hindered by the inability to accurately quantitate 
the risk modulation engendered by the joint effects 
of  genetics and environmental factors. Moreover, the 
inadequacy of  conventional statistical approaches to 
model the complex nature of  many of  the CRC risk 
factors further limits application of  these data to patient 
management. While landmark studies have explored 
the age of  CRC diagnosis in HNPCC[8], these estimates 
along with others in the literature have not yet factored 
in the genetic/environmental influences that determine 
the phenotypic heterogeneity. The focus of  our study 
was on this phenotypic heterogeneity which is of  major 
importance to clinicians who care for these challenging 
patients. We believe that by knowing the genetic and 
environmental risk factors, we can individualize more 
accurately the risk analysis, which, to our knowledge, has 
not been previously reported.
    One approach from the engineering literature that has 
recently received attention for cancer risk assessment 
is fuzzy logic. This powerful modeling technique has 
been successfully used for pattern recognition and image 
processing and its unique ability to transcend the typical 
black or white approaches in standard modeling and to 
capture the “shades of  gray” has great promise for clinical 
medicine[9]. While typical statistical approaches function 
well when the data are normally distributed and values 
are near the mean, this approach is often inadequate at 
the threshold. For instance, a very high prostate specific 
antigen (PSA) has excellent predictive ability for prostate 
cancer, but the optimal clinical management of  a patient 
with a mildly elevated value is unclear. Fuzzy logic 
overcomes these limitations of  conventional statistics 
by allowing partial membership function. In our PSA 
example, instead of  categorizing values as either normal 
or abnormal, a fuzzy approach would allow one to place 
a value as one quarter in the normal group and three-
quarters in the abnormal group. Thus, through the creation 
of  fuzzy sets, elements can have degrees of  membership 
on a continuum (e.g. a value can be “normal, slightly 
elevated, moderately elevated or highly elevated”).
    Another unique attribute of  fuzzy modeling is that, 
unlike traditional models, it does not require prior 
knowledge of  the system being modeled. It is a “model-
free” form in which natural rules are developed from the 
data rather than imposing rules on the modeling system. 
The result of  this “model-free” system is still a conversion 
from inputs to outputs, similar to traditional algorithms[10]. 
Another strength of  fuzzy modeling lies in its ability 
to model data points that may be outside of  traditional 
inclusion boundaries and thus allowing accurate modeling 
with less data.
    Past reports have demonstrated that fuzzy modeling 
can improve performance characteristics of  tumor 
markers over conventional applications[11-13]. Our previous 
work with conventional statistical approaches (COX 
proportional hazard modeling) indicated that tobacco 
use, gender and mutated gene play an important role in 
phenotypic presentation of  CRC progression in HNPCC 
patients as a group, but lack the ability to predict an 
individual risk of  CRC (e.g. not sensitive to dose effects 
or interactions of  factors). We, therefore, explored the 
ability of  fuzzy modeling to predict CRC risk in germline 
mutation carriers in these individual HNPCC patients by 
factoring the gene type, gender and tobacco use status in 
the present study.
MATERIALS AND METHODS
Database
The Hereditary Cancer Center at Creighton University 
is one of  the oldest and largest registries for diverse 
hereditary cancer syndrome, containing information on 
over 200 000 individuals of  whom approximately 600 
are verified MMR mutation carriers (Lynch Database). 
The database contains patient and family information, 
surveillance and treatment information as well as gene 
mutations and lifestyle data. The inclusion criteria were 
HNPCC as documented by either a MMR germline 
mutation positivity or clinical HNPCC from a patient who 
had a family member with a documented MMR mutation. 
For example, if  the patient has HNPCC and his mother 
has a documented hMSH2 mutation, we would consider 
the patient to have an hMSH2 mutation. Tobacco data 
were obtained by self-report and family report or by 
abstraction from medical records. A patient was classified 
as a tobacco user if  he/she reported ever regularly using (or 
was reported to have ever regularly used) cigarettes, cigars, 
a pipe, tobacco chew, or snuff. Five hundred and ninety-six 
mutation carriers were identified from 62 HNPCC families. 
For this analysis we only focused on cigarette smokers. 
Of  these, 340 (60.4%) had information on tobacco use 
and were included in our study (158 nonsmokers and 
182 smokers). In a further analysis, 271 patients (113 of  
182 smokers and 158 nonsmokers) with a more detailed 
smoking history including calculated pack-years were 
selected. 
Modeling    
The entire modeling procedure was performed using 
the MatLab Fuzzy Toolbox (Matlab, Version 6.1-Release 
13, Natick, MA). Figure 1 provides an overview of  
the basic fuzzy modeling algorithm. The data (either 
categorical or continuous) were inputted into the program 
and a clustering algorithm led to the development of  
membership functions. The fuzzy clustering method 
used produces descriptions of  each of  the input vectors 
as belonging to one (or more) fuzzy sets with a specific 
membership in each of  the sets. The inclusion of  a 
continuous variable (pack-years and age) produces non-
catagorical (aka, fuzzy) memberships. Rules are then 
developed from these membership functions which 
successfully produce a mapping from the input space to 
the output space as previously described[10]. Furthermore, 
Data Membership
function
Clustering
System optimization
Rules
Output Refined
output
Figure 1  Overview of fuzzy methodology.
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these rules represent fuzzy relationships between the 
variables, even if  the variables themselves are categorical. 
The refinement of  these rules is accomplished using the 
Adaptive Neural Fuzzy Inference System (ANFIS; 16) 
which acts as a feedback loop to further refine the rules 
until they are optimized to give the best fit to the data. 
Overfitting of  the model to the data is not exclusively 
addressed. However, the clustering methods (subtractive 
clustering) employed in the modeling scheme tend to 
partition the data space in such a manner as to maximize 
the cluster density while simultaneously maximizing the 
separation of  the clusters which would limit overfitting.
    This modeling technique was applied to the patients 
selected from the Lynch database with gene mutation, sex, 
smoking status and age as the input and risk of  developing 
colorectal cancer as the output. In a second study, the 
effect of  pack years was added as an additional input. 
In this case, dividing a group of  smokers with a given 
mutation, sex and age further by smoke years made the 
numbers in each group quite small. We therefore used the 
data as the training set and a theoretical set of  conditions 
as the input to generate the model output. The models 
produced a cumulative risk of  CRC that ranged between 0 
and 1. Age and pack years were fuzzified in the program.
Statistical analysis   
Results are presented either as a scattergram of  the actual 
model output for each patient in the database (Figures 2-4) 
or as an output of  the model given a set of  theoretical 
conditions (Figure 5). The statistical procedures used 
followed the methods described by Steel and Torrie[14]. The 
data for each cohort were paired and compared using a 
Kolmagrov-Smirnov (KS) 2-sample test. The KS test was 
considered to be conservative and useful when hypothesis 
about discrete distributions was tested. The test is 
motivated by the need to compare 2 independent samples 
and the null hypothesis is that each sample originates from 
identical distributions (i.e., the data are from the same 
population). Critical values for the KS test are inversely 
proportional to the square root of  the total number of  
observations. The nature of  our data dictated that the 
critical values were computed using unequal populations (n1 
≠ n2). Furthermore, the nature of  the data and results only 
required a comparison of  this type. Other analyses, such 
as a test of  trend or analysis of  variance, were not deemed 
beneficial.
RESULTS
Smoking status 
The influence of  genetic mutation combined with sex, 
smoking status and age is demonstrated in Figure 2. 
There was a clear impact of  cigarette smoking on the age-
adjusted risk of  developing CRC for all conditions tested 
(gene mutated and gender).  
    When a male patient with the hMSH2 gene mutation 
car rier smokes, he markedly increased his r isk of  
developing CRC by up to 2.4-fold at the age of  78 (Figure 
2D, P < 0.05). In the case of  a mutation in the hMLH1 
gene, smoking increased the risk of  CRC at the maximal 
age tested by approximately 1.3-fold for males when 
compared to non-smokers (Figure 2B). Females with the 
hMLH1 mutation showed a 1.3-fold increased risk of  
developing CRC and female smokers with the hMSH2 
mutation had a 1.4-fold greater risk of  developing CRC 
when compared to their non-smoking age-matched 
controls (Figures 2A and 2C).
Gene 
The model output was then reexamined as a function of  
the genetic mutation (Figure 3). For males, patients with 
a hMLH1 mutation had either a 2.5- or a 1.3-fold greater 
risk of  developing CRC than those with a hMSH2 for non-
smokers and smokers respectively (Figures 3B and 3D, P < 
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Figure 2  Scattergram demonstrating the 
probability of developing CRC (cumulative 
lifetime risk) for each subject based on 
smoking status, ▲= Smokers, □ = Non-
Smokers. Data are divided by gene mutation 
and sex wi th (A ) hMLH1: Female, (B ) 
hMLH1: Male, (C) hMSH2: Female and (D) 
hMSH2: Male (P < 0.05).      
0     10    20    30    40     50    60    70     80
               Age
0     10    20    30    40     50    60    70     80
               Age
0     10    20    30    40     50    60    70     80
               Age
0     10    20    30    40     50    60    70     80
               Age
A
C D
B
Brand RM et al.  Fuzzy modeling of colon cancer risk in HNPCC                                                              4487
www.wjgnet.com
www.wjgnet.com
0.05). The difference was greater for the non-smokers than 
the smokers because subjects with hMSH2 who smoke 
increased their rate of  CRC greater than the non-smokers. 
Female non-smokers with the hMLH1 mutation showed a 
1.5-fold increase in CRC risk as compared to the hMSH2 
subjects, whereas it was 1.4-fold higher for smokers.    
Gender  
Figure 4 demonstrates that males had a greater risk of  
developing CRC than females when compared to an 
equivalent age, gene mutation and smoking status. Males 
had a significantly higher risk of  CRC than females 
(1.5-fold) for non-smoking subjects with the hMLH1 
mutations (Figure 4A, P < 0.05) and smokers (1.6-fold) 
(Figure 4B, P < 0.1). Smoking males with the hMSH2 
mutation also had a greater risk of  CRC than hMSH2 
mutation harboring females by 1.6-fold (Figure 4D, P 
< 0.01), but the gender effect dissipated in nonsmokers 
(Figure 4C, P > 0.05).
Smoking dose response 
A subset of  the data which had an estimate of  pack years 
was then modeled to determine if  there was an association 
between lifetime quantities of  cigarettes smoked and risk 
of  CRC. The mean consumption was 24-pack years for 
patients who smoked cigarettes. Figure 5 demonstrates the 
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Figure 4  Scattergram demonstrating the 
probability of developing CRC (cumulative 
lifetime risk) for each subject based on 
gender, △ = female, ▼=male.  Data are 
divided by gene mutation and smoking 
status with (A) hMLH1: non-smokers, (B) 
hMLH1: smokers (P < 0.1), (C) hMSH2: 
non-smokers (P > 0.05) and (D) hMSH2: 
smokers (P < 0.1). The P values show 
the probability of failing to reject the null 
hypothesis that the data originate from 
identical populations, indicating that the 
curves are different.
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Figure 3  Scattergram demonstrating the 
probability of developing CRC (cumulative 
lifetime risk) for each subject based on 
genetic mutation, ◊ = hMLH1, ● = hMSH2. 
Data are divided by sex and smoking 
status with (A) Female: non-smokers (P < 
0.001), (B) Female: smokers (P < 0.001), 
(C) Male: non-smokers (P < 0.001) and (D) 
Male: smokers (P < 0.05). The P values 
show the probability failing to reject the 
null hypothesis that the data originate from 
identical populations, indicating that the 
curves are different.
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risk of  developing CRC as a function of  pack years. For 
female smokers with a hMLH1 mutation (Figure 5A), the 
CRC risk was only increased after 30-pack years (P < 0.01), 
whereas for males (Figure 5B) the risk did not significantly 
increase until 40-pack years (P < 0.05). Similarly, females 
with a hMSH2 (Figure 5C) only demonstrated a smoking 
effect at 40-pack years (P < 0.01). Conversely, males with 
a hMSH2 mutation (Figure 5D) had an increased risk of  
developing CRC in a dose-dependent fashion in response to 
the number of  cigarettes smoked over their lifetime (P < 0.01).
DISCUSSION
We have demonstrated herein that by using a fuzzy 
modeling approach, we could quantitatively predict the 
effect of  environmental factors on risk of  developing CRC 
in subjects who harbor a germline mutation for HNPCC. 
Importantly, we could calculate estimates for the impact 
of  modifiable risk factors (i.e. smoking) on the occurrence 
of  CRC in these high-risk patients and individualize the 
risk estimates by accounting for other major factors on the 
phenotypic variability in HNPCC patients: the mutated 
gene (hMLH1 versus hMSH2) and gender. Thus, we 
believe that these results may be a useful tool in patient 
counseling by providing concrete estimates of  the impact 
of  risk factor modification.
    Our observations regarding the gene-environmental 
joint effects were made possible by the remarkable 
resource represented by the Creighton Hereditary Cancer 
Center Registry. Although it is one of  the oldest and 
largest HNPCC registries in the world, a conventional 
statistical approach to this dataset is not powerful enough 
to detect the gene-environment joint effect and the dose-
response of  smoking and CRC[15], because the relatively 
small subgroup size markedly reduces statistical power 
in conventional (e.g. Cox proportional hazard modeling) 
statistical approaches. One approach to mitigate these 
concerns is to increase the size of  groups (e.g. to evaluate 
effect of  age by increasing 40-59, 60-79, etc). However, 
such large groups have clear disadvantages. For instance, 
a 41-year old individual and a 58-year old individual may 
be quite biologically/ clinically different and yet are in the 
same stratum. Fuzzy modeling enables partial membership 
functions. For instance, a 43-year old individual may 
be considered to be 80% in the 40-50 group and 20% 
belonging to the 30-39 category, whereas a 59-year old 
individual may be 65% in the 50-59 group and 35% 
within the 60-70 group. Thus, fuzzy modeling allows us to 
account for the heterogeneity, i.e., “shades of  gray” that is 
a hallmark of  clinical medicine.
    There are several lines of  evidence that support the 
biological validity of  our findings with fuzzy modeling. 
Cigarette use is an important risk factor for CRC, and 
12% of  all CRC deaths are attributed to smoking[16]. Many 
studies indicate that cigarette smoking can increase the 
incidence of  colon cancers by approximately two fold, 
however there are numerous contradictory reports[17-19]. 
These discordant data have been clar if ied by the 
demonstration that cigarette smoking may selectively 
increase the risk for DNA mismatch repair[20]. This may 
be related to the observation that smoking preferentially 
promotes microsatellite unstable (MSI-high) tumors. 
The molecular pathway is also seen in Lynch syndrome 
tumors[19]. For instance, Yang et al[21] have recently reported 
that cigarette smoking increases the risk of  developing 
MMR-deficient tumors by 3.1-fold. Additionally, Slattery 
et al[22] demonstrated that smoking 20 cigarettes per day 
increases the risk of  MMR-deficient tumors by 1.6-fold in 
men (95% CI = 1.0-2.5) and 2.2-fold in women (95% CI 
= 1.4-3.5). Furthermore, they have documented a dose-
dependent relationship between smoking and colorectal 
cancer [22]. This dose-dependence underscores the 
plausibility of  the cigarette-induced CRC risk. While we 
were able to discern an effect of  smoking in our previous 
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study in HNPCC- cigarette smoking data set with Cox 
proportional hazard modeling, the lack of  dose response 
raises concerns about the validity of  the findings [15]. 
Using fuzzy modeling we demonstrated a much clearer 
relationship. For instance, our dose response model 
predicts that female smokers with a hMLH1 mutation 
who have at least 30-pack years of  smoking will have an 
increase in the lifetime risk of  CRC by 2.2- fold. A 3.3-fold 
increase is seen for females with an hMSH2 mutation after 
40 pack years. Males with a hMSH2 mutation have a more 
linear increase in their lifetime risk of  developing CRC as a 
function of  pack years.
    This ability to quantitate an individual’s risk is of  
paramount clinical importance due to the variability in 
CRC presentation that is characteristic of  HNPCC. For 
instance, some members of  a kindred may develop CRC 
at age 25 and 65 while other members may never develop 
it. Given this heterogeneity, “one size fits all” approach 
to management (the current state of  the art) is clearly 
inadequate. Indeed, previous attempts to determine 
the optimal cancer prevention strategy (prophylactic 
colectomy versus colonoscopic surveillance) have failed 
to conclusively demonstrate the superiority of  any single 
approach[7]. Even determining the best colonoscopic 
intervals is unclear. While our group recommends annual 
colonoscopy starting at age 25 [23], a large number of  
negative examinations are expensive and have potential 
complications and may lead to patient complacency. 
Increasing surveillance intervals is fraught with danger 
given both the rapid adenoma to carcinoma transition 
and also the flat nature of  the lesions, leading to a higher 
possibility of  lesions being missed on colonoscopy[23]. The 
consequences of  inadequate screening are underscored 
by the report of  Jarvinen and colleagues[24], who noted 
that over a 15-year observation period, 8.4% of  HNPCC 
patients who did not undergo screening would die of  CRC 
whereas none of  those who were in a screening program 
can succumb to this malignancy. Indeed, in mutation 
positive subjects, development of  CRC occur in 42% 
of  the non-screened but only 18% in patients receiving 
screening (P < 0.02)[24]. Thus, implementation and 
adherence of  a screening regimen are critical in protecting 
these high-risk patients against CRC.
    It needs to be emphasized that the ability of  fuzzy 
modeling to quantitate risk may be of  considerable 
importance in counseling patients. For instance, being able 
to tell patients that their risk of  CRC more than doubles 
with smoking may be more tangible than stating that 
smoking is detrimental to ones health, thereby providing 
a greater impetus for behavior modification. By accurately 
delineating risk, patients will be able to concretely identify 
modifiable risk factors and ascertain the impact of  their 
lifestyle changes, thus providing positive reinforcement. 
In this regard, Halpert and colleagues[25] noted that genetic 
testing of  HNPCC patients may have a profound effect 
upon motivation for cancer prevention strategies such as 
colonoscopy. Improved adherence with CRC screening 
regimens from genetic testing and counseling is also 
documented by Hadley and associates[26]. The malleability 
of  CRC prevention behaviors in HNPCC patients is 
further highlighted by Adams and colleagues[27] who 
documented the effect of  socio-economic considerations 
on age of  resection of  CRC in HNPCC patients. Thus, we 
believe that added information obtained by fuzzy modeling 
may have a dramatic effect on patient behavior and thus 
outcomes. There are previous demonstrations of  the 
efficacy of  fuzzy logic to cancer risk stratification. Fuzzy 
logic has been used with impressive success to improve the 
sensitivity of  tumor markers in diagnosing cancer[11-13].
    There are several limitations of  this report that need 
to be acknowledged. As any modeling, the accuracy of  
the results is dependent on quality of  the data inputted. 
Many of  our patients did not have data to quantitate pack-
years. Bias in the database due to patient/family report is 
possible (e.g. having cancer may influence recollection of  
tobacco use history). Since tobacco use is not a “standard” 
risk-factor for CRC, we do not think this will impact 
the results. With smoking, there is always concern about 
confounding from “competing causes of  mortality”[28]. 
However we have recently shown that this effect is 
negligible for the smoking-CRC effect[29]. Finally, while our 
modeling accurately reflects our database, the algorithms 
need to be validated in other databases.
    In conclusion, a fuzzy modeling approach represents 
a promising means of  predict ing the phenotypic 
heterogeneity in colorectal cancer presentation in HNPCC 
mutation carriers. The methodology may be an important 
tool in unraveling the gene-environment joint effects 
in hereditary cancer syndromes. Furthermore, this may 
serve as the basis for future paradigms that determine 
individualized cancer prevention strategies in subjects 
harboring an inherited risk.
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